With over 20 years of extensive experience in corporate finance, public company accounting and audit, regulatory compliance and stock exchange reporting, Yan-Klassen brings a wealth of knowledge covering a wide range of industries while holding important positions at several accounting firms, including five years as senior manager at BDO Canada LLP.
As both a chartered professional accountant and a certified management accountant, Yan-Klassen has also had considerable practice in complex tax calculations and models involving multiple jurisdictions and foreign currency issues and assisted with real estate trust wind-ups and distributions, mortgage investment corporations with valuations analysis and reporting, as well as private companies and charities with assurance work, including tax and information returns.
“We’re thrilled to have Steve join our roster of experienced clinical, regulatory and bioengineering professionals who have worked so hard to advance our SkinGun technology over the years,” stated Thomas Bold, president of RenovaCare. “To date, over 70 patients have been experimentally treated, with many leaving the hospital in a matter of days, avoiding painful and expensive skin graft surgery. These results, along with other important factors, are why we were able to report positive outcomes from our pre-submission meeting with the U.S. FDA.”
The SkinGun technology has been validated in numerous peer-reviewed scientific papers and widely-covered in mainstream media. To see first-hand remarkable ‘before-after’ patient recovery using the SkinGun, please watch this video.
The company has developed its novel SkinGun for the ultra-gentle spray of a patient’s own skin stem cells onto burns and wounds for rapid healing. The potent, regenerative cells are isolated from a postage stamp sized donor site and suspended in a liquid, the CellMist Solution. The CellMist Solution is then sprayed onto wounds using the SkinGun. The entire procedure can be completed in as little as 90 minutes.
The SkinGun spray device and cell isolation methodology are subjects of patents awarded to RenovaCare in the United States and Europe. The company has also filed additional patent applications in its continuing efforts to expand its intellectual property portfolio.
*RenovaCare products are currently in development. They are not available for sale in the United States.
RenovaCare Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patient’s stem cells—the CellMist Solution— onto wounds. RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the United States alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.